subtilisin-like proprotein convertase
Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)
... significantly in LDLc exposed cells compared to cells without LDLc exposure (Fig. 5a, b). In long-term sur- vival assay, pre-treatment and presence of LDLc during sorafenib treatment resulted in the survival of more ...
16
The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations
... Proprotein convertase subtilisin-like kexin type 9 (PCSK9, OMIM 607786) is a newly discovered serine protease that plays a key role in LDL-C homeostasis by mediating LDL receptor (LDLR) ...
15
Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes
... The proprotein convertase subtilisin/kexin type 9 (PCSK9) has been reported to play an important role in the development of atherosclerosis; PCSK9 mono- clonal antibodies (mAbs), including evolocumab ...
12
IDENTIFICATION OF POTENTIAL INHIBITORS FOR LOWERING CHOLESTEROL LEVEL BY INHIBITING PCSK9
... Proprotein convertase subtilisin kexin 9 (PCSK9) is the family of proprotein convertases. The main function of PCSK9 is to activate other protein by cleaving the sections of peptide chains. ...
5
Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population
... Proprotein convertase subtilisin/kexin type 9 (PCSK9), the ninth member of the proprotein convertase family, has been investigated extensively in the field of lipid me- tabolism ...
8
Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study
... We previously carried out an open label efficacy and safety 24-week study of ALI and EVO in 72 patients with HeFH and/or CVD with suboptimal LDL choles- terol (LDLC) lowering on maximal tolerated cholesterol lowering ...
11
Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) consensus on the usage of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
... Many reports have revealed that PCSK-9 has a critical role in the life cycle of the LDL receptors [18]. LDL re- ceptors are clustered in clathrin-coated pits on the sur- face of hepatocytes. After binding to LDL, an ...
6
Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease
... Lp(a) is a LDL-like particle synthesized by the liver, that consists of an apoB100 molecule linked to a very large glycoprotein known as the apolipoprotein(a) [8, 24]. The biological role of Lp(a) is uncertain; ...
7
The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol
... Abstract: Proprotein convertase subtilisin/kexin type 9 (PCSK9) directly binds to the epidermal growth factor-like repeat A domain of low-density lipoprotein receptor and induces its degrada- ...
14
The Regulation of Proprotein Convertase Subtilisin/ Kexin Type 9 and Its Liver Involvement
... apoptosis-regulated convertase 1 (NARC - 1) and its expression was found not only in hepatocytes, but also in some epithelial cells (from intestine and colon), mesenchymal cells (from kidney) and brain ...
12
The associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis
... Proprotein convertase subtilisin/kexin type 9 (PCSK9), originally named neural apoptosis regulated convertase- 1 (NARC-1), is the ninth member of the proprotein con- vertase family ...
12
Proprotein convertase furin regulates osteocalcin and bone endocrine function
... 7 subtilisin/kexin-like PCs, resulted in a similar molecular shift of either endogenous OCN secreted from primary osteoblast cultures or a V5-tagged version transfected in osteo- blasts or in CHO-ldlD cells ...
15
Inhibition of PCSK9 protects against radiation-induced damage of prostate cancer cells
... Abbreviations: PcsK9, proprotein convertase subtilisin/kexin type 9; sirna, small interfering rna; ir, ionizing radiation; cyto c, cytochrome c; Bcl-2, B-cell leukemia/ lymphoma 2; Bax,[r] ...
8
Structure and properties of proprotein convertase inhibitors
... Изучение действия указанных соедине ний на другие ПК показало, что синтезирован ные тетрапептиды действуют на РАСЕ4, РС5/6 и РС1/3 человека сходным образом (значения K i для соедине[r] ...
25
Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders
... Abstract: The aim of this manuscript is to review available data to evaluate the present status of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of hypercho- ...
13
Myeloid cell expressed proprotein convertase FURIN attenuates inflammation
... Tumor Necrosis Factor Alpha Converting Enzyme; ADAM17: ADAM Metallopeptidase Domain 17; Ptgs2: Cyclooxygenase-2; CXCL: C-X-C motif Chemokine; CCL: Chemokine (C-C motif) Ligand; Serpinb1a: Serine (or cysteine) peptidase ...
13
Hypercholesterolaemia and vascular dementia
... Oxidative stress and lipid oxidation in particular have a pivotal role in the development of VaD [43]; lipid peroxid- ation may influence neuronal membrane permeability, affecting cellular function and damaging ...
18
The elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels
... Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a major role in lipoprotein clearance by promoting intracellular lysosomal degradation of the LDLR, the VLDL receptor (VLDLR) and the LRP ...
8
Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk
... Alirocumab is a fully human monoclonal antibody that binds to and inhibits proprotein convertase subtilisin/ kexin type 9 (PCSK9), a key regulator of plasma LDL-C metabolism. Alirocumab is approved ...
10
Linking melanism to brain development: expression of a melanism-related gene in barn owl feather follicles covaries with sleep ontogeny
... precocial chicken (Gallus gallus domesticus) and the al- tricial magpie (Pica pica). However, the results remain contradictory and/or confounded by environmental fac- tors known to influence the expression of REM sleep. ...
12